# Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer

> **NCT02516670** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 50 (actual)

## Conditions studied

- Hormone-Resistant Prostate Cancer
- Metastatic Prostate Carcinoma
- Stage IV Prostate Cancer

## Interventions

- **DIETARY_SUPPLEMENT:** Ascorbic Acid
- **DRUG:** Docetaxel
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **OTHER:** Placebo
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT02516670
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06-20
- **Primary completion:** 2021-07-31
- **Final completion:** 2021-10-14
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** insufficient clinical response per DSMB
- **Last updated:** 2023-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02516670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02516670, "Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02516670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*